Publications 1998

Edler L. Computational statistics for pharmacokinetic data analysis. In: COMPSTAT. Proceedings in Computational Statistics. Payne R., Green P. (eds), Heidelberg: Physica, pp.281-286 (1998).

Edler L., Jung D., Flesch-Janys D., Portier C.J., Pilz L., Clark G., Lucier G., Konietzko J. Herz-Kreislauf-Erkrankungen und ihre Risikofaktoren nach beruflicher Exposition gegenüber Dioxinen und Furanen. Arbeitsmed. Sozialmed. Umweltmed. (Sonderheft 24): 48-53 (1998).

Edler L.Evidence based conclusions on the efficacy of a treatment. What can be learned from risk assessment? In: Nonrandomized Comparative Clinical Studies. Abel U., Koch A. (eds), Düsseldorf: Symposion Publ. pp.53-65 (1998).

Edler L.6/12/5000 Pharmakokinetik. In: Verfahrensbibliothek. Versuchsplanung und Auswertung. vol.II Rasch D., Herrendörfer G., Bock J., Victor N., Guiard V. (eds), Lehr- und Handbücher der Statistik. Schlittgen R. München: R.Oldenburg, pp.629-638 (1998).

Edler L., Pilz L., Pötschke-Langer M. Cancer prevention in childhood. Intention of future smoking explored in the Heidelberg children health study. J. Cancer Res. Clin. Oncol. 124: R19(1998). (Abstract)

Edler L.6/12/4000 Präklinische Versuche. In: Verfahrensbibliothek. Versuchsplanung und Auswertung. vol.II, Rasch D., Herrendörfer G., Bock J., Victor N., Guiard V. (eds), Lehr- und Handbücher der Statistik. Schlittgen R. München: R.Oldenburg, (1998).

Edler L., Kopp-Schneider A. Statistical models for low dose exposure. Mut. Res. 405 (2): 227-236 (1998).

Faisst S., Guittard D., Benner A., Cresbon J.Y., Schlehofer J.R., Rommelaere J., Dupressoir T. Dose-dependent regression of HeLa cell-derived tumours in SCID mice after parvovirus H-1 infection. Int. J. Cancer 75 (4): 584-589 (1998).

Franz A., Queisser W., Hartung G., Sturm J., Edler L., Bornbusch D., Dietrich G., Böllinger C., Gonnermann M., Wojatschek C., Brauckhoff M., Studiengruppe Mannheim: Prospective study of adjuvant therapy with monoclonal antibody 17-1A of Dukes' B2/B3 colon carcinoma. First analysis of toxicity. Onkol. 21: (1998). (Abstract)

Gleissner B., Hellmann A., Berdel W.E., Edler L., Koldehoff M., Rost A., Opri F.S., Fritze D., Öhl S. Phase I/II study of paclitaxel and 5-fluorouracil as second-line therapy in patients with metastatic breast cancer. Onkol. 21: 305-308 (1998).

Hack V., Breitkreutz R., Kinscherf R., Rohrer H., Bartsch P., Taut F., Benner A., Dröge W. The redox state as a correlate of senescence and wasting and as a target for therapeutic intervention. Blood 29 (1): 59-67 (1998).

Hartung G., Queisser W., Manegold C., Diezler P., Hagmüller E., Edler L., Bauer A., Pabst T., Wojatschek C., Jannsen N. Radio-chemotherapy with 5-Fluorouracil and folinic acid in stage II and III rectal cancer: Comparison of 6 vs 12 months treatment. Onkol. 21: 563(1998). (Abstract)

Jung D., Berg P.A., Edler L., Ehrenthal W., Fenner D., Flesch-Janys D., Huber C., Klein R., Koitka C., Lucier G., Manz A., Muttray A., Needham L., Päpke O., Pietsch M., Portier C.J., Patterson D., Prellwitz W., Rose D.M., Thews A., Konietzko J. Immunologische Befunde bei ehemals gegenüber 2,3,7,8-Tetrachlordibenzodioxin (TCDD) und seinen Kongeneren exponierten Arbeitern in der Pestizidherstellung. Arbeitsmed. Sozialmed. Umweltmed. (Sonderheft 24): 38-43 (1998).

Konstantinov S.M., Topashka-Ancheva M., Benner A., Berger M.R. Alkylphosphocholines: Effects on human leukemic cell lines and normal bone marrow cells. Int. J. Cancer 77 (5): 778-786 (1998).

Kopp-Schneider A., Portier C.J., Bannasch P. A model for hepatocarcinogenesis treating phenotypical changes in focal hepatocellular lesions as epigenetic events. Math. Biosci. 148 (2): 181-204 (1998).

Kreuser E.D., Fiebig H.H., Scheulen M.E., Hanauske A.R., Keppler B.K., Mross K.B., Schalhorn A., Eisenbrand G., Edler L., Höffken K., Berdel W.E. Standard operating procedures and organization of German phase I, II, and III study groups, new drug development group (AWO), and study group of pharmacology in oncology and hematology (APOH) of the association for medical oncology (AIO) of the German cancer society. Onkol. 21 (Suppl.3)(1998).

Liliensiek B., Rocha M., Umansky V., Benner A., Lin J., Ziegler R., Nawroth P.P., Schirrmacher V. Identification of four genes in endothelial cells whose expression is affected by tumor cells and host immune status. A study in ex vivo-isolated endothelial cells. Blood 92 (9): 3394-3404 (1998).

Masten S.A., Grassman J.A., Miller C.R., Spencer D.L., Walker N.J., Jung D., Edler L., Patterson D.G.j., Needham L.L., Lucier G.W. Population-based studies of dioxin responsiveness: Individual variation in CYP1A1 levels and relationship to dioxin body burden. Organohalogen Comp. 38: 13-16 (1998).

Mayer D., Metzger C., Leonetti P., Beier K., Benner A., Bannasch P. Differential expression of key enzymes of energy metabolism in preneoplastic and neoplastic rat liver lesions induced by n-nitrosomorpholine and dehydoepiandrosterone. Int. J. Cancer 79 (3): 232-240 (1998).

Moos M., Schulz R., Martin S., Benner A., Haas R. The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukem. 12: 1971-1976 (1998).

Müller-Decker K., Kopp-Schneider A., Marks F., Seibert K., Fürstenberger G. Localization of prostaglandin H-synthase isoenzymes in murine epidermal tumors: Suppression of skin tumor promotion by inhibition of prostaglandin H synthase -2. Mol. Carcinogen. 23: 36-44 (1998).

Pawel J.v., Gatzemeier U., Mehl B., Edler L., Baumgart J., Drings P. Clinical phase II trial of Treosulfan in patients with non-resectable non-small-cell lung cancer. Onkol. 21: 316-319 (1998).

Pilz L., Edler L., Pötschke-Langer M. Cancer risk factors in fourth and fifth grade pupils. First results from the Heidelberg children health study. J. Cancer Res. Clin. Oncol. 124: R145(1998). (Abstract)

Pilz L., Edler L., Pötschke-Langer M. Statistical evaluation of health risk factors from the Heidelberg children health study. In: Methoden der Medizinischen Informatik, Biometrie und Epidemiologie in der modernen Informationsgesellschaft. vol.83 Greiser E., Wischnewsky M. (eds), Medizinische Informatik, Biometrie und Epidemiologie. Überla K., Rienhoff O., Victor N. München: MMV Medien&Medizin, pp.483-486 (1998).

Rojas M., Alexandrov K., Cascorbi I., Brockmöller J., Likhachev A., Pozharisski K., Bouvier G., Auburtin G., Mayer L., Kopp-Schneider A., Roots I., Bartsch H. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/MspI-GSTM1*0/*0 genotypes. Pharmacogen. 8: 109-118 (1998).

Stricker K., Knipping E., Böhler T., Benner A., Krammer P.H., Debatin K.M. Anti-CD95 (APO-1/Fas) autoantibodies and T cell depletion in human immunodeficiency virus type 1 (HIV-1)-infected children. Cell Death Diff. 5: 222-230 (1998).

Ströbel P., Klimek F., Zerban H., Kopp-Schneider A., Bannasch P. Xenomorphic hepatocellular percursors and neoplastic progression of tigroid cell foci induced in rats with low doses of N-nitrosomorpholine. Carcinogen. 19: 2069-2080 (1998).

Volm M., Koomägi R., Rittgen W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous cell lung carcinoma. Int. J. Cancer 79 (3): 294-299 (1998).

Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Brit. J. Cancer 77 (4): 663-669 (1998).

Weber R.G., Bridger J.M., Benner A., Weisenberger D., Ehemann V., Reifenberger G., Lichter P. Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations. Cytogenet. Cell Genet. 83: 266-269 (1998).

Weber R.G., Bridger J.M., Benner A., Weisenberger D., Ehemann V., Reifenberger G., Lichter P. Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with mutant p53. Clin. Neuropath. 15: 242(1998). (Abstract)

Weh H.J., Zschaber R., Braumann D., Hölzer P., Hoffmann R., Becker K., Kleeberg U.R., Pompecki R., Hoffknecht M., Benner A., Hossfeld D.K. A randomised phase III study comparing weekly folinic acid (FA) and high-dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal carcinoma. Onkol. 21: 403-407 (1998).

Weitz J., Kienle P., Lacroix J., Willecke F., Benner A., Lehnert T., Herfarth C., v.Knebel-Doeberitz M. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin. Cancer Res. 4 (2): 343-348 (1998).